1. Search Result
Search Result
Results for "

cardiac volume

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-18402

    Drug Derivative Cardiovascular Disease
    2-(Methylthio)benzothiazole is a derivative of 2-Mercaptobenzothiazole (HY-W017113). 2-(Methylthio)benzothiazole reduces heart rate, causes pericardial edema and deformity, delays cardiac maturation, decreases stroke volume and cardiac output, and leads to vascular structural defects in zebrafish larvae .
    2-(Methylthio)benzothiazole
  • HY-105011A

    Angiotensin Receptor Cardiovascular Disease
    YM-358 hydrate potassium is an orally active angiotensin II type 1 (AT1)-receptor antagonist. YM-358 hydrate potassium can decrease cardiac volume overload. YM-358 hydrate potassium can be used for the research of cardiovascular disease, such as hypertension .
    YM-358 hydrate potassium
  • HY-P1428A

    Neuropeptide Y Receptor Cardiovascular Disease
    RFRP-1(human) TFA is a potent endogenous NPFF receptor agonist (EC50 values are 0.0011 and 29 nM for NPFF2 and NPFF1, respectively). Attenuates contractile function of isolated rat and rabbit cardiac myocytes. Reduces heart rate, stroke volume, ejection fraction and cardiac output, and increases plasma prolactin levels in rats.
    RFRP-1(human) TFA
  • HY-B1116A

    (-)-Metaraminol; (-)-erythro-Metaraminol; (-)-m-Hydroxynorephedrine

    Adrenergic Receptor Neurological Disease
    Metaraminol ((-)-Metaraminol) is a sympathomimetic compound with activity that acts primarily at alpha-1 adrenergic receptors. Metaraminol is used to inhibit hypotension due to vasodilation, particularly in critically ill patients who do not respond well to volume resuscitation. Metaraminol may also be used as an adjunct to help improve cardiac contractility. The use of metaraminol may be supported by less evidence, but its effectiveness in specific situations remains of interest .
    Metaraminol
  • HY-134043

    Chlorthalidone EP Impurity G

    Carbonic Anhydrase Cardiovascular Disease
    Chlorthalidone Impurity G (Chlorthalidone EP Impurity G) is a potential impurity found in commercial preparations of chlorthalidone with moderate antihypertensive effects. Chlorthalidone is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal tubule of the kidney, thereby preventing sodium and chloride reabsorption, resulting in decreased plasma volume and cardiac output. It also inhibits carbonic anhydrase (CA), including isoenzymes CAVB, VII, IX, XII, and XIII (Kis=2.8-23 nM) and to a lesser extent CAI, CAII, IV, VA, and VI (Ki=138-1,347 nM), mediating vasodilatory activity.
    Chlorthalidone Impurity G
  • HY-149796

    Adrenergic Receptor Cardiovascular Disease
    Tazolol is a specific β-adrenergic antagonist (IC50: 700 nM for (-) isoproterenol-elicited accumulation of cyclic AMP in rat cortical slices). Tazolol produces a significant and sustained increase in cardiac output and stroke volume. Tazolol can be used in the research of heart failure .
    Tazolol
  • HY-182252

    Na+/Ca2+ Exchanger Cardiovascular Disease
    SAR296968 is a Na +/Ca 2+ exchanger (NCX) subtype inhibitor with an IC50 value of 74 nM against hNCX1. SAR296968 inhibits both forward and reverse modes of NCX current. SAR296968 enhances cardiac contractility and stroke volume. SAR296968 exerts antiarrhythmic effects. SAR296968 is applicable to research related to heart failure .
    SAR296968

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: